Trial Profile
A Multicenter Phase II/III Double-Blind, Randomized, Placebo Controlled Study To Evaluate The Efficacy And Safety Of VPM1002 In The Prevention Of Tuberculosis (TB) Recurrence In Pulmonary TB Patients After Successful TB Treatment
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 10 Apr 2024
Price :
$35
*
At a glance
- Drugs BCG vaccine (Primary)
- Indications Tuberculosis
- Focus Therapeutic Use
- Sponsors Serum Institute of India
- 05 Apr 2024 Planned End Date changed from 1 Feb 2024 to 30 Jul 2024.
- 05 Apr 2024 Planned primary completion date changed from 1 Feb 2024 to 30 Apr 2024.
- 11 Apr 2023 Planned End Date changed from 30 May 2022 to 1 Feb 2024.